Last $2.06 USD
Change Today +0.03 / 1.48%
Volume 269.1K
CPRX On Other Exchanges
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

catalyst pharmaceutical part (CPRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/3/13 - $3.65
52 Week Low
05/1/13 - $0.68
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

catalyst pharmaceutical part (CPRX) Related Businessweek News

No Related Businessweek News Found

catalyst pharmaceutical part (CPRX) Details

Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. The company focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. Its principal product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. The company also develops CPP-115, a vigabatrin analog to treat infantile spasms and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, such as post-traumatic stress disorder and Tourette syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.

7 Employees
Last Reported Date: 03/19/14
Founded in 2002

catalyst pharmaceutical part (CPRX) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $426.5K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $231.0K
Chief Operating Officer and Chief Scientific ...
Total Annual Compensation: $309.4K
Compensation as of Fiscal Year 2013.

catalyst pharmaceutical part (CPRX) Key Developments

Catalyst Pharmaceutical Partners Inc. Announces Completion of Enrollment in Pivotal Phase 3 Trial of Firdapse in Patients With Lambert-Eaton Myasthenic Syndrome

Catalyst Pharmaceutical Partners Inc. announced that it has reached the patient enrollment target for its pivotal Phase 3 trial evaluating the safety and efficacy of Firdapse for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). Based on the enrollment and randomization success metrics achieved to date, the company believes that it has enrolled a sufficient number of LEMS patients to ensure that 36 patients will be randomized into the double-blind, placebo-controlled, discontinuation portion of the trial. The company continues to screen additional, previously identified LEMS patients who have expressed interest in participating in this study. As allowed in the protocol for this study, all LEMS patients who are not randomized can continue to receive Firdapse as participants in the two-year follow-up period. The Firdapse Phase 3 trial utilizes a randomized, double-blind, placebo-controlled, discontinuation design. The trial is being conducted at 22 sites in the United States, Canada, South America and Europe. After enrolled patients have been treated with Firdapse for at least 91 days, they are randomly assigned to either continue on Firdapse or be discontinued to placebo over a 2-week period. Following the randomization phase of the trial, patients then receive open label Firdapse treatment for a two-year follow-up period, to obtain additional long term safety and efficacy data. The primary endpoint of the Phase 3 trial is a comparison of changes in patients randomized to continue Firdapse versus those who transition to placebo that occur in both the QMG score, which measures muscle strength, and subject global impression score, on which the subject rates their global impression of the effects of a study treatment during a 14-day double-blind efficacy evaluation period. The secondary endpoints are change in the investigator's assessment of worsening of disease symptoms and changes in walking speed (Timed 25-foot walking test) during the two-week, double-blind testing period.

Catalyst Pharmaceutical Partners, Inc. Appoints Barrett S. Mcgrath as Chief Commercial Officer

Catalyst Pharmaceutical Partners Inc. announced the appointment of Barrett S. McGrath as Chief Commercial Officer, a newly created position. McGrath will lead the formation of Catalyst's North America commercial strategy and organization. McGrath will report to Patrick McEnany, Chairman, President and Chief Executive Officer of Catalyst. In his most recent industry role, Barrett was the Vice President, Commercial Development at InterMune Inc. This role began in May 2009 following a 13-month consulting relationship with the company. In both capacities, his primary responsibility was to develop the U.S. commercial strategy and organization in preparation for the launch of Esbriet(R) (pirfenidone), which is the only approved medicine for idiopathic pulmonary fibrosis (IPF), a large orphan disease, in Europe and Canada.

Catalyst Pharmaceutical Partners, Inc. Reports Earnings Results for the Full Year Ended December 31, 2013

Catalyst Pharmaceutical Partners Inc. has reported that net loss for the year ended December 31, 2013 was $12.15 million, or $0.27 loss per share, compared to net loss of $4.08 million, or $0.14 loss per share, for the year ended December 31, 2012. Loss from operations for the year ended December 31, 2013 was $10.31 million, compared to a loss from operations of $5.22 million for the year ended December 31, 2012. Total assets as of December 31, 2013 were $25.37 million, compared to $16.79 million as of December 31, 2012.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPRX:US $2.06 USD +0.03

CPRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CPRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation CPRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CATALYST PHARMACEUTICAL PART, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at